Chemists at The Scripps Research Institute (TSRI) have
determined the correct structure of a highly promising anticancer compound
approved by the U.S. Food and Drug Administration (FDA) for clinical trials in
cancer patients.
The new report, published this week by the international
chemistry journal Angewandte Chemie, focuses on a compound called TIC10.